Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib.

ABSTRACT:

Background

Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that not only improves heart failure caused by various factors but also plays a role in mediating apoptosis in tumor cells. However, the role of dapagliflozin in sunitinib-induced cardiotoxicity remains unclear.

Methods

Immunodeficient mice were subcutaneously injected with RCC cells to establish a xenograft tumor model, and were treated with sunitinib and dapagliflozin to explore the impact of dapagliflozin on the antitumor effects of sunitinib and its cardiac toxicity. Additionall

SUBMITTER: Huang SY 

PROVIDER: S-EPMC12821901 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature